| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2025 | Mar 27, 2025 | Prelude Therapeutics Inc | CEO | Buy | 97.5 | +675,000 | 22.54% | ✗ | $467.4K |
| Mar 20, 2025 | Mar 24, 2025 | Prelude Therapeutics Inc | CEO | Buy | 68.8 | +20,416 | 0.69% | ✗ | $14.9K |
| Mar 14, 2025 | Mar 18, 2025 | Prelude Therapeutics Inc | CEO | Buy | 78.8 | +39,105 | 1.33% | ✗ | $29.5K |
| Mar 12, 2025 | Mar 14, 2025 | Prelude Therapeutics Inc | CEO | Buy | 87.5 | +97,500 | 3.44% | ✗ | $69.6K |
| Dec 31, 2024 | Jan 3, 2025 | Prelude Therapeutics Inc | CEO | Buy | 55.0 | +5,000 | 0.18% | ✗ | $6K |
| Dec 30, 2024 | Jan 2, 2025 | Prelude Therapeutics Inc | CEO | Buy | 61.3 | +10,000 | 0.35% | ✗ | $12K |
| Dec 18, 2024 | Dec 20, 2024 | Prelude Therapeutics Inc | CEO | Buy | 87.5 | +106,888 | 3.94% | ✗ | $99.3K |
| May 24, 2023 | May 26, 2023 | Prelude Therapeutics Inc | CEO | Buy | 55.0 | +1,900 | 0.07% | ✗ | $9.8K |
| May 23, 2023 | May 25, 2023 | Prelude Therapeutics Inc | CEO | Buy | 65.0 | +11,856 | 0.44% | ✗ | $66.7K |
| Dec 20, 2022 | Dec 21, 2022 | Prelude Therapeutics Inc | CEO | Buy | 72.5 | +19,188 | 0.72% | ✗ | $98.4K |